A Clinical study to Evaluate the Efficacy and Safety of Unani Formulation (Itrifal Mulayyin) in the management of Shaqiqa Muzmin (Chronic Migraine)

A Clinical study to Evaluate the Efficacy and Safety of Unani Formulation (Itrifal Mulayyin) in the management of Shaqiqa Muzmin (Chronic Migraine) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054994

Enrollment

Registered

2023-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G438- Other migraine

Interventions

Intervention1: Itrifal Mulayyin: 5gm twice a day orally for 45 days Control Intervention1: not applicable: not applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed Patients with chronic migraine as per ICHD criteria 2.Patients aged between 18-60 years 3. Either gender 4. Willing to fill daily headache diary 5. Patient willing to sign written informed consent

Exclusion criteria

Exclusion criteria: 1. Non-migrainous headache: tension-type headache; cluster headache; chronic paroxysmal or non-paroxysmal hemicranias 2. Familial hemiplegic migraine 3. Below 18 and above 60 years 4. Pregnancy and Lactating women 5. Patients with Neuropsychiatric illness 6. Patients with significant co-morbidity

Design outcomes

Primary

Measure	Time frame
1. Visual Analogue scale (VAS) 2. Migraine disability assessment (MIDAS) Timepoint: Baeseline ,0,15,35,45 days	—

Secondary

Measure	Time frame
Itrifal Mulayyin is effective in chronic migraine Timepoint: 0 & 45 day	—

Countries

India

Contacts

Public ContactDr Usamah Ahmad

State Unani Medical College And Hospital

asifhussainusmani@gmail.com7905831926

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026